Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia? (Q38091393)

28 August 2017

Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia? (English)

1 reference

28 August 2017

1 reference

1 reference

Felicetto Ferrara

1

1 reference

28 August 2017

20 March 2013

1 reference

28 August 2017

Hematological Oncology

1 reference

28 August 2017

32

1 reference

28 August 2017

1

1 reference

28 August 2017

1-9

1 reference

Acute myeloid leukaemia in adults

28 August 2017

1 reference

Genetic abnormalities and challenges in the treatment of acute myeloid leukemia

21 January 2018

1 reference

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

21 January 2018

1 reference

New prognostic markers in acute myeloid leukemia: perspective from the clinic

21 January 2018

1 reference

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

21 January 2018

1 reference

Clinically useful prognostic factors in acute myeloid leukemia

21 January 2018

1 reference

Has there been progress in the treatment of older patients with acute myeloid leukemia?

21 January 2018

1 reference

Acute myeloid leukaemia in the elderly: a review

21 January 2018

1 reference

Acute myeloid leukemia in older adults

21 January 2018

1 reference

Age and acute myeloid leukemia

21 January 2018

1 reference

Acute myeloid leukemia in the real world: why population-based registries are needed

21 January 2018

1 reference

Survival for older patients with acute myeloid leukemia: a population-based study

21 January 2018

1 reference

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

21 January 2018

1 reference

A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly

21 January 2018

1 reference

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

The hematopoietic growth factors in acute leukemia: a European perspective

21 January 2018

1 reference

Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review

21 January 2018

1 reference

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

21 January 2018

1 reference

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

Clofarabine: emerging role in leukemias

21 January 2018

1 reference

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

21 January 2018

1 reference

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

21 January 2018

1 reference

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

Induction and postremission strategies in acute myeloid leukemia: what is new?

21 January 2018

1 reference

Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?

21 January 2018

1 reference

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

21 January 2018

1 reference

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

21 January 2018

1 reference

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

21 January 2018

1 reference

What is the role of reduced-intensity transplantation in the treatment of older patients with AML?

21 January 2018

1 reference

Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

21 January 2018

1 reference

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

21 January 2018

1 reference

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.

21 January 2018

1 reference

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

21 January 2018

1 reference

Farnesyltransferase inhibitors: where are we now?

21 January 2018

1 reference

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

21 January 2018

1 reference

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

21 January 2018

1 reference

Gene silencing by DNA methylation in haematological malignancies

21 January 2018

1 reference

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences

21 January 2018

1 reference

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

21 January 2018

1 reference

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

21 January 2018

1 reference

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

21 January 2018

1 reference

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

21 January 2018

1 reference

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

21 January 2018

1 reference

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

21 January 2018

1 reference

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

21 January 2018

1 reference

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

21 January 2018

1 reference

Treatment of older patients with acute myeloid leukaemia

21 January 2018

1 reference

7 January 2021

Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge

1 reference

7 January 2021

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

1 reference

7 January 2021

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

7 January 2021

Vulnerable and frail elderly: An approach to the management of the main tumour types

1 reference

7 January 2021

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

7 January 2021

Chromatin modifying agents - the cutting edge of anticancer therapy

1 reference

7 January 2021

Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: for all, none, or which patients?

1 reference

7 January 2021

Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.2046

1 reference

release_dhhwu4kzlvgdhlok4hvrcwkpou

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dhhwu4kzlvgdhlok4hvrcwkpou

24 November 2022

mapped directly with Wikidata item

PubMed ID

23512815

1 reference

PubMed ID

23512815